Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza; Caitrin Fretham; Stephanie J. Lee; Mukta Arora; Janet Brunner; Saurabh Chhabra; Steven Devine; Mary Eapen; Mehdi Hamadani; Parameswaran Hari; Marcelo C. Pasquini; Waleska Perez; Rachel A. Phelan; Marcie L. Riches; J. Douglas Rizzo; Wael Saber; Bronwen E. Shaw; Stephen R. Spellman; Patricia Steinert; Daniel J. Weisdorf; Mary M. Horowitz

doi:10.1016/j.bbmt.2020.04.013

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza, Caitrin Fretham, Stephanie J. Lee, Mukta Arora, Janet Brunner, Saurabh Chhabra, Steven Devine, Mary Eapen, Mehdi Hamadani, Parameswaran Hari, Marcelo C. Pasquini, Waleska Perez, Rachel A. Phelan, Marcie L. Riches, J. Douglas Rizzo, Wael Saber, Bronwen E. Shaw, Stephen R. Spellman, Patricia Steinert, Daniel J. WeisdorfMary M. Horowitz

Research output: Contribution to journal › Review article › peer-review

365 Scopus citations

Abstract

Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.

Original language	English (US)
Pages (from-to)	e177-e182
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	8
DOIs	https://doi.org/10.1016/j.bbmt.2020.04.013
State	Published - Aug 2020

Bibliographical note

Funding Information:
Financial disclosure:The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 with the National Cancer Institute (NCI) the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/Cooperative Agreement U24HL138660 with the NHLBI and NCI; Grant U24CA233032 from the NCI; Grants OT3HL147741, R21HL140314, K23HL141445, and U01HL128568 from the NHLBI; Contract HHSH250201700006C with the Health Resources and Services Administration (HRSA); grants N00014-18-1-2888, N00014-17-1-2850, and N00014-20-1-2705 from the Office of Naval Research; Biomedical Advanced Research and Development Authority Grant HHS0100201800012C; a subaward from prime contract Award SC1MC31881-01-00 with the HRSA; subawards from prime Grant Awards R01 HL131731 and R01 HL126589 from the NHLBI; subaward from prime Grant Award 5R01 CA2151343 from the NCI; Grants P01 CA111412, R01 CA152108, R01 CA218285, R01 CA231141, R01 HL126589, R01 HL129472, R01 HL131731, and U01 AI126612 from the NIH; and corporate funds from AbbVie, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne, Allovir, Amgen, Anthem, Astellas Pharma US, Atara Biotherapeutics, bluebird bio, Bristol Myers Squibb, Celgene, Chimerix, CSL Behring; CytoSen Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Enterprise Science and Computing, Gamida Cell, Genzyme, GlaxoSmithKline, HistoGenetics, Immune Deficiency Foundation, Incyte, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jazz Pharmaceuticals, Kiadis Pharma, Kite Pharma, Kyowa Kirin, Magenta Therapeutics, Medac, Merck & Company, Merck Sharp & Dohme, Mesoblast, Millennium, Miltenyi Biotec, Montefiore Medical Center, Novartis Oncology, Novartis Pharmaceuticals, Omeros, Oncoimmune, Orca Biosystems, Pfizer, Phamacyclics, Regeneron Pharmaceuticals, REGiMMUNE, Sanofi Genzyme, Seattle Genetics, Shire, Sobi, Takeda Oncology, Takeda Pharma, Viracor Eurofins, and Xenikos BV and nonprofit funds from Be the Match Foundation; National Marrow Donor Program, St Baldrick's Foundation, and The Medical College of Wisconsin.

Funding Information:
The authors thank the CIBMTR Statistical Operations, Data Operations, Information Technology, and Biostatistical Support teams, who contribute to the collection and use of quality data. They also acknowledge the Data Management teams from all reporting centers. Financial disclosure:The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 with the National Cancer Institute (NCI) the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/Cooperative Agreement U24HL138660 with the NHLBI and NCI; Grant U24CA233032 from the NCI; Grants OT3HL147741, R21HL140314, K23HL141445, and U01HL128568 from the NHLBI; Contract HHSH250201700006C with the Health Resources and Services Administration (HRSA); grants N00014-18-1-2888, N00014-17-1-2850, and N00014-20-1-2705 from the Office of Naval Research; Biomedical Advanced Research and Development Authority Grant HHS0100201800012C; a subaward from prime contract Award SC1MC31881-01-00 with the HRSA; subawards from prime Grant Awards R01 HL131731 and R01 HL126589 from the NHLBI; subaward from prime Grant Award 5R01 CA2151343 from the NCI; Grants P01 CA111412, R01 CA152108, R01 CA218285, R01 CA231141, R01 HL126589, R01 HL129472, R01 HL131731, and U01 AI126612 from the NIH; and corporate funds from AbbVie, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne, Allovir, Amgen, Anthem, Astellas Pharma US, Atara Biotherapeutics, bluebird bio, Bristol Myers Squibb, Celgene, Chimerix, CSL Behring; CytoSen Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Enterprise Science and Computing, Gamida Cell, Genzyme, GlaxoSmithKline, HistoGenetics, Immune Deficiency Foundation, Incyte, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jazz Pharmaceuticals, Kiadis Pharma, Kite Pharma, Kyowa Kirin, Magenta Therapeutics, Medac, Merck & Company, Merck Sharp & Dohme, Mesoblast, Millennium, Miltenyi Biotec, Montefiore Medical Center, Novartis Oncology, Novartis Pharmaceuticals, Omeros, Oncoimmune, Orca Biosystems, Pfizer, Phamacyclics, Regeneron Pharmaceuticals, REGiMMUNE, Sanofi Genzyme, Seattle Genetics, Shire, Sobi, Takeda Oncology, Takeda Pharma, Viracor Eurofins, and Xenikos BV and nonprofit funds from Be the Match Foundation; National Marrow Donor Program, St Baldrick's Foundation, and The Medical College of Wisconsin. Conflict of interest statement: There are no conflicts of interest to report.

Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy

Keywords

Activity
Hematopoietic cell transplantation
Summary slides

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.bbmt.2020.04.013

Find It

Find It at U of M Libraries

Cite this

D'Souza, A., Fretham, C., Lee, S. J., Arora, M., Brunner, J., Chhabra, S., Devine, S., Eapen, M., Hamadani, M., Hari, P., Pasquini, M. C., Perez, W., Phelan, R. A., Riches, M. L., Rizzo, J. D., Saber, W., Shaw, B. E., Spellman, S. R., Steinert, P., ... Horowitz, M. M. (2020). Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biology of Blood and Marrow Transplantation, 26(8), e177-e182. https://doi.org/10.1016/j.bbmt.2020.04.013

D'Souza, A, Fretham, C, Lee, SJ, Arora, M, Brunner, J, Chhabra, S, Devine, S, Eapen, M, Hamadani, M, Hari, P, Pasquini, MC, Perez, W, Phelan, RA, Riches, ML, Rizzo, JD, Saber, W, Shaw, BE, Spellman, SR, Steinert, P, Weisdorf, DJ & Horowitz, MM 2020, 'Current Use of and Trends in Hematopoietic Cell Transplantation in the United States', Biology of Blood and Marrow Transplantation, vol. 26, no. 8, pp. e177-e182. https://doi.org/10.1016/j.bbmt.2020.04.013

@article{245b5073078546d7bb5aa05c016c176c,

title = "Current Use of and Trends in Hematopoietic Cell Transplantation in the United States",

abstract = "Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.",

keywords = "Activity, Hematopoietic cell transplantation, Summary slides",

author = "Anita D'Souza and Caitrin Fretham and Lee, {Stephanie J.} and Mukta Arora and Janet Brunner and Saurabh Chhabra and Steven Devine and Mary Eapen and Mehdi Hamadani and Parameswaran Hari and Pasquini, {Marcelo C.} and Waleska Perez and Phelan, {Rachel A.} and Riches, {Marcie L.} and Rizzo, {J. Douglas} and Wael Saber and Shaw, {Bronwen E.} and Spellman, {Stephen R.} and Patricia Steinert and Weisdorf, {Daniel J.} and Horowitz, {Mary M.}",

note = "Funding Information: Financial disclosure:The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 with the National Cancer Institute (NCI) the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/Cooperative Agreement U24HL138660 with the NHLBI and NCI; Grant U24CA233032 from the NCI; Grants OT3HL147741, R21HL140314, K23HL141445, and U01HL128568 from the NHLBI; Contract HHSH250201700006C with the Health Resources and Services Administration (HRSA); grants N00014-18-1-2888, N00014-17-1-2850, and N00014-20-1-2705 from the Office of Naval Research; Biomedical Advanced Research and Development Authority Grant HHS0100201800012C; a subaward from prime contract Award SC1MC31881-01-00 with the HRSA; subawards from prime Grant Awards R01 HL131731 and R01 HL126589 from the NHLBI; subaward from prime Grant Award 5R01 CA2151343 from the NCI; Grants P01 CA111412, R01 CA152108, R01 CA218285, R01 CA231141, R01 HL126589, R01 HL129472, R01 HL131731, and U01 AI126612 from the NIH; and corporate funds from AbbVie, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne, Allovir, Amgen, Anthem, Astellas Pharma US, Atara Biotherapeutics, bluebird bio, Bristol Myers Squibb, Celgene, Chimerix, CSL Behring; CytoSen Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Enterprise Science and Computing, Gamida Cell, Genzyme, GlaxoSmithKline, HistoGenetics, Immune Deficiency Foundation, Incyte, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jazz Pharmaceuticals, Kiadis Pharma, Kite Pharma, Kyowa Kirin, Magenta Therapeutics, Medac, Merck & Company, Merck Sharp & Dohme, Mesoblast, Millennium, Miltenyi Biotec, Montefiore Medical Center, Novartis Oncology, Novartis Pharmaceuticals, Omeros, Oncoimmune, Orca Biosystems, Pfizer, Phamacyclics, Regeneron Pharmaceuticals, REGiMMUNE, Sanofi Genzyme, Seattle Genetics, Shire, Sobi, Takeda Oncology, Takeda Pharma, Viracor Eurofins, and Xenikos BV and nonprofit funds from Be the Match Foundation; National Marrow Donor Program, St Baldrick's Foundation, and The Medical College of Wisconsin. Funding Information: The authors thank the CIBMTR Statistical Operations, Data Operations, Information Technology, and Biostatistical Support teams, who contribute to the collection and use of quality data. They also acknowledge the Data Management teams from all reporting centers. Financial disclosure:The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 with the National Cancer Institute (NCI) the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/Cooperative Agreement U24HL138660 with the NHLBI and NCI; Grant U24CA233032 from the NCI; Grants OT3HL147741, R21HL140314, K23HL141445, and U01HL128568 from the NHLBI; Contract HHSH250201700006C with the Health Resources and Services Administration (HRSA); grants N00014-18-1-2888, N00014-17-1-2850, and N00014-20-1-2705 from the Office of Naval Research; Biomedical Advanced Research and Development Authority Grant HHS0100201800012C; a subaward from prime contract Award SC1MC31881-01-00 with the HRSA; subawards from prime Grant Awards R01 HL131731 and R01 HL126589 from the NHLBI; subaward from prime Grant Award 5R01 CA2151343 from the NCI; Grants P01 CA111412, R01 CA152108, R01 CA218285, R01 CA231141, R01 HL126589, R01 HL129472, R01 HL131731, and U01 AI126612 from the NIH; and corporate funds from AbbVie, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne, Allovir, Amgen, Anthem, Astellas Pharma US, Atara Biotherapeutics, bluebird bio, Bristol Myers Squibb, Celgene, Chimerix, CSL Behring; CytoSen Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Enterprise Science and Computing, Gamida Cell, Genzyme, GlaxoSmithKline, HistoGenetics, Immune Deficiency Foundation, Incyte, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jazz Pharmaceuticals, Kiadis Pharma, Kite Pharma, Kyowa Kirin, Magenta Therapeutics, Medac, Merck & Company, Merck Sharp & Dohme, Mesoblast, Millennium, Miltenyi Biotec, Montefiore Medical Center, Novartis Oncology, Novartis Pharmaceuticals, Omeros, Oncoimmune, Orca Biosystems, Pfizer, Phamacyclics, Regeneron Pharmaceuticals, REGiMMUNE, Sanofi Genzyme, Seattle Genetics, Shire, Sobi, Takeda Oncology, Takeda Pharma, Viracor Eurofins, and Xenikos BV and nonprofit funds from Be the Match Foundation; National Marrow Donor Program, St Baldrick's Foundation, and The Medical College of Wisconsin. Conflict of interest statement: There are no conflicts of interest to report. Publisher Copyright: {\textcopyright} 2020 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = aug,

doi = "10.1016/j.bbmt.2020.04.013",

language = "English (US)",

volume = "26",

pages = "e177--e182",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

AU - D'Souza, Anita

AU - Fretham, Caitrin

AU - Lee, Stephanie J.

AU - Arora, Mukta

AU - Brunner, Janet

AU - Chhabra, Saurabh

AU - Devine, Steven

AU - Eapen, Mary

AU - Hamadani, Mehdi

AU - Hari, Parameswaran

AU - Pasquini, Marcelo C.

AU - Perez, Waleska

AU - Phelan, Rachel A.

AU - Riches, Marcie L.

AU - Rizzo, J. Douglas

AU - Saber, Wael

AU - Shaw, Bronwen E.

AU - Spellman, Stephen R.

AU - Steinert, Patricia

AU - Weisdorf, Daniel J.

AU - Horowitz, Mary M.

N1 - Funding Information: Financial disclosure:The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 with the National Cancer Institute (NCI) the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/Cooperative Agreement U24HL138660 with the NHLBI and NCI; Grant U24CA233032 from the NCI; Grants OT3HL147741, R21HL140314, K23HL141445, and U01HL128568 from the NHLBI; Contract HHSH250201700006C with the Health Resources and Services Administration (HRSA); grants N00014-18-1-2888, N00014-17-1-2850, and N00014-20-1-2705 from the Office of Naval Research; Biomedical Advanced Research and Development Authority Grant HHS0100201800012C; a subaward from prime contract Award SC1MC31881-01-00 with the HRSA; subawards from prime Grant Awards R01 HL131731 and R01 HL126589 from the NHLBI; subaward from prime Grant Award 5R01 CA2151343 from the NCI; Grants P01 CA111412, R01 CA152108, R01 CA218285, R01 CA231141, R01 HL126589, R01 HL129472, R01 HL131731, and U01 AI126612 from the NIH; and corporate funds from AbbVie, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne, Allovir, Amgen, Anthem, Astellas Pharma US, Atara Biotherapeutics, bluebird bio, Bristol Myers Squibb, Celgene, Chimerix, CSL Behring; CytoSen Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Enterprise Science and Computing, Gamida Cell, Genzyme, GlaxoSmithKline, HistoGenetics, Immune Deficiency Foundation, Incyte, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jazz Pharmaceuticals, Kiadis Pharma, Kite Pharma, Kyowa Kirin, Magenta Therapeutics, Medac, Merck & Company, Merck Sharp & Dohme, Mesoblast, Millennium, Miltenyi Biotec, Montefiore Medical Center, Novartis Oncology, Novartis Pharmaceuticals, Omeros, Oncoimmune, Orca Biosystems, Pfizer, Phamacyclics, Regeneron Pharmaceuticals, REGiMMUNE, Sanofi Genzyme, Seattle Genetics, Shire, Sobi, Takeda Oncology, Takeda Pharma, Viracor Eurofins, and Xenikos BV and nonprofit funds from Be the Match Foundation; National Marrow Donor Program, St Baldrick's Foundation, and The Medical College of Wisconsin. Funding Information: The authors thank the CIBMTR Statistical Operations, Data Operations, Information Technology, and Biostatistical Support teams, who contribute to the collection and use of quality data. They also acknowledge the Data Management teams from all reporting centers. Financial disclosure:The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement U24CA076518 with the National Cancer Institute (NCI) the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/Cooperative Agreement U24HL138660 with the NHLBI and NCI; Grant U24CA233032 from the NCI; Grants OT3HL147741, R21HL140314, K23HL141445, and U01HL128568 from the NHLBI; Contract HHSH250201700006C with the Health Resources and Services Administration (HRSA); grants N00014-18-1-2888, N00014-17-1-2850, and N00014-20-1-2705 from the Office of Naval Research; Biomedical Advanced Research and Development Authority Grant HHS0100201800012C; a subaward from prime contract Award SC1MC31881-01-00 with the HRSA; subawards from prime Grant Awards R01 HL131731 and R01 HL126589 from the NHLBI; subaward from prime Grant Award 5R01 CA2151343 from the NCI; Grants P01 CA111412, R01 CA152108, R01 CA218285, R01 CA231141, R01 HL126589, R01 HL129472, R01 HL131731, and U01 AI126612 from the NIH; and corporate funds from AbbVie, Actinium Pharmaceuticals, Adaptive Biotechnologies, Adienne, Allovir, Amgen, Anthem, Astellas Pharma US, Atara Biotherapeutics, bluebird bio, Bristol Myers Squibb, Celgene, Chimerix, CSL Behring; CytoSen Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Enterprise Science and Computing, Gamida Cell, Genzyme, GlaxoSmithKline, HistoGenetics, Immune Deficiency Foundation, Incyte, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jazz Pharmaceuticals, Kiadis Pharma, Kite Pharma, Kyowa Kirin, Magenta Therapeutics, Medac, Merck & Company, Merck Sharp & Dohme, Mesoblast, Millennium, Miltenyi Biotec, Montefiore Medical Center, Novartis Oncology, Novartis Pharmaceuticals, Omeros, Oncoimmune, Orca Biosystems, Pfizer, Phamacyclics, Regeneron Pharmaceuticals, REGiMMUNE, Sanofi Genzyme, Seattle Genetics, Shire, Sobi, Takeda Oncology, Takeda Pharma, Viracor Eurofins, and Xenikos BV and nonprofit funds from Be the Match Foundation; National Marrow Donor Program, St Baldrick's Foundation, and The Medical College of Wisconsin. Conflict of interest statement: There are no conflicts of interest to report. Publisher Copyright: © 2020 American Society for Transplantation and Cellular Therapy

PY - 2020/8

Y1 - 2020/8

N2 - Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.

AB - Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.

KW - Activity

KW - Hematopoietic cell transplantation

KW - Summary slides

UR - http://www.scopus.com/inward/record.url?scp=85085969206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085969206&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2020.04.013

DO - 10.1016/j.bbmt.2020.04.013

M3 - Review article

C2 - 32438042

AN - SCOPUS:85085969206

SN - 1083-8791

VL - 26

SP - e177-e182

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 8

ER -

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this